Physician profile
Seth Michael Webber
NPI 1982675153
$6,626.81
in general payments reported to CMS, 2019-2025
31 companies · $1,167 in 2025
The $1,167 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,390 · 2020: $664 · 2021: $750 · 2022: $817 · 2023: $1,056 · 2024: $784 · 2025: $1,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,006.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,897.58 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $927.44 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Qol Medical, LLC | $747.20 | 2021-2025 | Sucraid, Sucraid |
| Novo Nordisk INC | $723.81 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $503.43 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $227.20 | 2019-2025 | Capvaxive, Dificid |
| Ardelyx, INC. | $196.74 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $166.89 | 2019-2025 | Omvoh, Jardiance, Mounjaro |
| Janssen Biotech, INC. | $152.11 | 2019-2025 | Tremfya, Stelara |
| Ferring Pharmaceuticals INC. | $129.63 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.47 | 2019-2025 | Jardiance, Stiolto Respimat, Cyltezo |
| Exact Sciences Corporation | $110.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $107.91 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.55 | 2019-2025 | Entyvio |
| Allergan, INC. | $74.90 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $58.86 | 2019 | |
| Celgene Corporation | $56.28 | 2022-2023 | Zeposia |
| Sanofi-Aventis U.S. LLC | $52.86 | 2020-2022 | |
| Abbott Laboratories | $52.01 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $42.14 | 2025 | Dexcom G6 Transmitter |
| Genzyme Corporation | $42.08 | 2024-2025 | |
| Braintree Laboratories, INC. | $25.17 | 2019-2022 | |
| Evoke Pharma, INC. | $19.00 | 2021 | |
| Amarin Pharma, INC. | $16.62 | 2020 | |
| Phathom Pharmaceuticals, INC. | $16.58 | 2025 | Voquezna |
| Gilead Sciences, INC. | $14.85 | 2025 | |
| Dova Pharmaceuticals | $14.20 | 2019 | |
| Redhill Biopharma INC. | $14.03 | 2021 | |
| Sanofi Pasteur INC. | $13.76 | 2019 | |
| Shionogi INC | $13.37 | 2019 | |
| Intercept Pharmaceuticals, INC. | $11.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Webber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.